{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:39:23Z","timestamp":1764859163429,"version":"3.37.3"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670146","81470318"],"award-info":[{"award-number":["81670146","81470318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cross Training Program of Shandong University","award":["2015JC052"],"award-info":[{"award-number":["2015JC052"]}]},{"name":"key research and development project of Shandong province","award":["2017GSF18109"],"award-info":[{"award-number":["2017GSF18109"]}]},{"name":"Medical and Health Technology Development Program in Shandong Province","award":["2016ws0371"],"award-info":[{"award-number":["2016ws0371"]}]},{"name":"Natural science fund of Shandong Province","award":["ZR2018PH013","ZR2019PH073"],"award-info":[{"award-number":["ZR2018PH013","ZR2019PH073"]}]},{"name":"Science Foundation of Qilu Hospital of Shandong University","award":["2016QLQN09","2017QLQN34"],"award-info":[{"award-number":["2016QLQN09","2017QLQN34"]}]},{"name":"Shandong Provincial Key Laboratory of Immunohematology Open Research Program","award":["2019XYKF006"],"award-info":[{"award-number":["2019XYKF006"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.biopha.2019.109413","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T10:11:24Z","timestamp":1568110284000},"page":"109413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation"],"prefix":"10.1016","volume":"119","author":[{"given":"Tao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"14","key":"10.1016\/j.biopha.2019.109413_bib0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2019.109413_bib0015","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2019.109413_bib0020","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/leu.2010.101","article-title":"BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients","volume":"24","author":"Marega","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.biopha.2019.109413_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2019.109413_bib0030","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1007\/s00277-015-2324-0","article-title":"Management of chronic myeloid leukemia in blast crisis","volume":"94","author":"Saussele","year":"2015","journal-title":"Ann. Hematol."},{"issue":"7043","key":"10.1016\/j.biopha.2019.109413_bib0035","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2019.109413_bib0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2019.109413_bib0045","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.18632\/oncotarget.2859","article-title":"Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.biopha.2019.109413_bib0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/cgt.2014.44","article-title":"The malignancy suppression role of miR-23a by targeting the BCR\/ABL oncogene in chromic myeloid leukemia","volume":"21","author":"Xishan","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2019.109413_bib0055","article-title":"MicroRNA-320a acts as a tumor suppressor by targeting BCR\/ABL oncogene in chronic myeloid leukemia","volume":"5","author":"Zhu","year":"2015","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2019.109413_bib0060","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression","volume":"13","author":"Bueno","year":"2008","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0065","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","author":"Liu","year":"2013","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.biopha.2019.109413_bib0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2015.03.023","article-title":"Wnt\/beta-Catenin activates MiR-183\/96\/182 expression in hepatocellular carcinoma that promotes cell invasion","volume":"362","author":"Leung","year":"2015","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.biopha.2019.109413_bib0075","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.18632\/oncotarget.2200","article-title":"HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96","volume":"5","author":"Feng","year":"2014","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.biopha.2019.109413_bib0080","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","article-title":"Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma","volume":"26","author":"Pal","year":"2007","journal-title":"EMBO J."},{"issue":"35","key":"10.1016\/j.biopha.2019.109413_bib0085","doi-asserted-by":"crossref","first-page":"23204","DOI":"10.1074\/jbc.M109.031427","article-title":"Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells","volume":"284","author":"Guttilla","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3892\/ol.2012.775","article-title":"miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer","volume":"4","author":"Guo","year":"2012","journal-title":"Oncol. Lett."},{"issue":"14","key":"10.1016\/j.biopha.2019.109413_bib0095","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1158\/0008-5472.CAN-09-4531","article-title":"miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer","volume":"70","author":"Yu","year":"2010","journal-title":"Cancer Res."},{"issue":"36","key":"10.1016\/j.biopha.2019.109413_bib0100","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/onc.2014.414","article-title":"Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway","volume":"34","author":"Siu","year":"2015","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1139\/bcb-2017-0183","article-title":"miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma","volume":"96","author":"Li","year":"2018","journal-title":"Biochem. Cell Biol."},{"issue":"24","key":"10.1016\/j.biopha.2019.109413_bib0110","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.febslet.2014.11.008","article-title":"miR-96 promotes osteogenic differentiation by suppressing HBEGF-EGFR signaling in osteoblastic cells","volume":"588","author":"Yang","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2019.109413_bib0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1746-1596-9-76","article-title":"Prognostic value of miR-96 in patients with acute myeloid leukemia","volume":"9","author":"Zhao","year":"2014","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.biopha.2019.109413_bib0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ebiom.2018.07.013","article-title":"The long noncoding RNA MEG3 and its target miR-147 regulate JAK\/STAT pathway in advanced chronic myeloid leukemia","volume":"34","author":"Li","year":"2018","journal-title":"Ebiomedicine"},{"issue":"6","key":"10.1016\/j.biopha.2019.109413_bib0125","first-page":"E507","article-title":"Inactivation of the microRNA-183\/96\/182 cluster results in syndromic retinal degeneration","volume":"110","author":"Turturro","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2019.109413_bib0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"issue":"37","key":"10.1016\/j.biopha.2019.109413_bib0135","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","article-title":"Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference (RNAi)","volume":"21","author":"Wilda","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2019.109413_bib0140","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","article-title":"Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)","volume":"102","author":"Wohlbold","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2009.016063","article-title":"Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib","volume":"95","author":"Koldehoff","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.biopha.2019.109413_bib0150","article-title":"Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0155","first-page":"3464","article-title":"miR-96 promotes breast cancer metastasis by suppressing MTSS1","volume":"15","author":"Xie","year":"2018","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2019.109413_bib0160","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ajpath.2012.01.008","article-title":"MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression","volume":"180","author":"Vishwamitra","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.biopha.2019.109413_bib0165","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1002\/jcb.27172","article-title":"miR-96 regulates migration and invasion of bladder cancer through epithelial-mesenchymal transition in response to transforming growth factor-\u03b21","volume":"119","author":"He","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0170","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-018-0450-6","article-title":"The miR-96 and RARgamma signaling axis governs androgen signaling and prostate cancer progression","volume":"38","author":"Long","year":"2019","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biopha.2019.109413_bib0175","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1101\/gad.1399806","article-title":"Control of translation and mRNA degradation by miRNAs and siRNAs","volume":"20","author":"Valencia-Sanchez","year":"2006","journal-title":"Genes Dev."},{"issue":"15","key":"10.1016\/j.biopha.2019.109413_bib0180","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1158\/0008-5472.CAN-05-3901","article-title":"c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2019.109413_bib0185","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ng1425","article-title":"Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia","volume":"36","author":"Graux","year":"2004","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2019.109413_bib0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12967-016-0893-x","article-title":"Regulatory mechanisms of microRNA expression","volume":"14","author":"Gulyaeva","year":"2016","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2019.109413_bib0195","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-Aza-2\u2019 deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2019.109413_bib0200","first-page":"3169","article-title":"Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2\/STAT3 signaling","volume":"8","author":"Zhao","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"4","key":"10.1016\/j.biopha.2019.109413_bib0205","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2019.109413_bib0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2019.109413_bib0215","doi-asserted-by":"crossref","DOI":"10.1002\/1873-3468.13521","article-title":"HDAC 2\u2010dependent mi RNA signature in acute myeloid leukemia","author":"Conte","year":"2019","journal-title":"FEBS Lett."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219322437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219322437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:06:15Z","timestamp":1731427575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219322437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":43,"alternative-id":["S0753332219322437"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109413","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"109413"}}